RESUMO
To determine whether iron(III)ethylenebis-(2-hydrophenylglycine) (Fe-EHPG), a prototype hepatobiliary magnetic resonance imaging agent, can enhance the liver-to-tumor contrast-to-noise ratio (C/N) in models of liver tumors in mice, two types of cell inoculation were used: intrahepatic implantation of M5076 sarcoma and intrasplenic injection of colon tumor (C-26) or M5076 sarcoma. Significant enhancement of the liver-to-tumor C/N and/or improved visualization of small lesions was consistently observed on T1-weighted images obtained after injection of the contrast material. For intrahepatic implants, the C/N on postinjection T1-weighted images was superior to that on T1- and T2-weighted preinjection images. For the C-26 metastatic liver lesions of larger diameter (greater than 5 mm), the C/N on postinjection T1-weighted studies was superior to that on preinjection T1-weighted images but was comparable to that on preinjection T2-weighted images. However, higher C/N after administration of Fe-EHPG improved visualization of medium-sized (3-5 mm) and small (1-3-mm) metastatic lesions in both M5076 and C-26 models. These results demonstrate that MR imaging with appropriate hepatobiliary agents appears promising for early detection of liver metastases.
Assuntos
Meios de Contraste , Etilenodiaminas , Neoplasias Hepáticas Experimentais/diagnóstico , Imageamento por Ressonância Magnética/métodos , Animais , Neoplasias do Colo/diagnóstico , Neoplasias Hepáticas Experimentais/secundário , Linfoma Difuso de Grandes Células B/diagnóstico , Camundongos , Camundongos Endogâmicos C57BL , Transplante de NeoplasiasAssuntos
Alanina/análogos & derivados , Antibióticos Antineoplásicos/uso terapêutico , Neoplasias Experimentais/tratamento farmacológico , Monofosfato de Adenosina/análogos & derivados , Monofosfato de Adenosina/metabolismo , Alanina/uso terapêutico , Animais , DNA/biossíntese , Resistência a Medicamentos , Leucemia L1210/tratamento farmacológico , Leucemia P388/tratamento farmacológico , Masculino , Camundongos , Proteínas do Tecido Nervoso/metabolismo , Nitrosaminas/uso terapêutico , Peptídeo Sintases/metabolismo , Succinatos/metabolismoRESUMO
Experiments are described in which four transplantable rodent tumors (L1210 lymphoid leukemia, P388 lymphocytic leukemia, B16 melanoma, and Walker 256 carcinosarcoma) were used to investigate the antitumor activity of amygdalin MF. Amygdalin MF was given alone and in combination with beta-glucosidase which was administered 1/2 hour prior to amygdalin MF, starting 24 hours after tumor implantation. No antitumor activity was observed in any of the four tumor systems tested with the drug alone or in combined therapy. The combined therapy showed potentiation of toxicity with doses of amygdalin MF greater than or equal to 100 mg/kg.